High-dose busulphan is an important component of many BMT conditioning regimens. High-dose busulphan therapy is associated with an increased risk of acute toxicity such as CNS toxicity and veno-occlusive disease (VOD). The toxicity was reported to correlate with a high AUC (area under the curve) during therapy. An intravenous form of busulphan would overcome the problems caused by inter-individual variability and bioavailability of busulphan and most probably minimize the problems with dose adjustment during therapy. The liposomal form of busulphan is an attractive alternative for intravenous administration of busulphan. In the present study, we compared the myeloablative effect of liposomal busulphan (LB) with that of the oral administration form and busulphan dissolved in organic solvent (Bus/DMSO) in mice. The pharmacokinetics of LB and Bus/DMSO were described by one compartment model while the oral data were fitted to one compartment model with first order absorption. The bioavailability of LB was 0.86 ؎ 0.02 compared to that obtained after the oral administration (0.40-0.74). Myelosuppression was determined using the colony-forming unit granulocyte-macrophage assay (CFU-GM) on days 1, 3, 6 and 9 after the conditioning regimen. LB resulted in significant myelosuppression from day 1 to day 9. The decrease in CFU-GM after conditioning regimen with LB was not significantly different from that observed after oral busulphan. Moreover, the administration of liposomes only to the mice did not affect the bone marrow. No side-effects of the liposomal formulation were observed. We suggest that the novel form of busulphan is a promising drug for clinical use.
oral form of the drug is available. The pharmacokinetics of the drug have been extensively studied during the last decade. These studies showed a great inter-patient variation due to age, circadian rhythmicity, underlaying diseases and drug-drug interaction. [4] [5] [6] [7] [8] [9] Recently it was also shown that busulphan bioavailability varies six-fold in children (0.22-1.2) and two-fold in adults (0.47-1.03). 6 Grochow et al 10 and Vassal et al 11 have shown that busulphan toxicity such as CNS toxicity and/or veno-occlusive disease (VOD) are correlated with the high systemic exposure expressed as AUC (area under the plasma concentration curve). During the last few years, several limited sampling models for monitoring of busulphan plasma levels have been established. The aim of these models was to individualize busulphan doses during conditioning regimens. 5, 12, 13 An intravenous form of busulphan may be a solution for the problems concerning the variability in bioavailability and the difficulties with dose adjustment in infants, young children and patients with gastrointestinal complications. Recently two studies have been reported using busulphan dissolved in organic solvents, dimethylsulfoxide (DMSO) and dimethylacetamide (DMA). 14, 15 However, these solvents have their own well-documented toxicity which has to be considered. [16] [17] [18] Recently, we reported liposomal busulphan as a possible alternative form for intravenous high-dose therapy. 19 Liposomes are phospholipid-based vesicles and are suitable for delivery of many drugs to specific sites of the body. 20 The distribution of liposomes is dependent on their size, charge and composition which makes it possible to target different organs. 21 Any drug regardless of its solubility can be incorporated into the liposomes due to their structural versatility. Amphotericin B, cis-platinum, methotrexate and doxorubicin are examples of clinical use of liposomal formulations. [22] [23] [24] In our previous study we showed that the bioavailability of liposomal busulphan (LB) was 0.85 in the rat. Moreover, we found that the distribution in bone marrow and spleen was significantly higher for LB than busulphan dissolved in DMSO and administered intravenously (Bus/DMSO). However, the distribution into brain, lungs and heart was significantly lower after the administration of LB compared to that obtained after Bus/DMSO. No difference in distribution into the liver comparing LB to Bus/DMSO was observed. We concluded that the novel formulation of liposomal busulphan seems to be a promising preparation for clinical trails, since it appears to target bone marrow and spleen with no accumulation in liver or other organs known for busulphan toxicity.
The aim of the present study was to investigate the effect of liposomal busulphan and busulphan in the oral form on bone marrow in a mouse model. We also investigated the pharmacokinetics and bioavailability of liposomal busulphan in mice.
Materials and methods

Chemicals
Busulphan (1,4-bis[methanesulfonoxy]butane) was obtained from the Wellcome Foundation, Beckenham, UK. Cholesterol, L-␣-phosphatidylcholine (egg, 100 mg/ml) and 1,2-dioleolyl-sn-glycero-3-phosphate (monosodium salt, 20 mg/ml) were obtained from Avanti Polar Lipids, Pelham, AL, USA. Dimethylsulfoxide, N,N-dimethylacetamide, propylene glycol and acetone were purchased from Merck, Darmstadt, Germany. PBS was provided by Karolinska Pharmacy, Stockholm, Sweden. Glucose 5% was obtained from Pharmacia-Upjohn (Uppsala, Sweden). Ammonium chloride solution and MethoCult M3530 were purchased from StemCell Technologies, Vancouver, Canada. MethoCult M3530 is a semisolid methylcellulose-based medium containing pokeweed mitogen-stimulated murine spleen cell conditioned medium (PWM-SCCM) as a source of colonystimulating factors. It supports the growth of CFU-G, CFU-M and CFU-GM.
Animals
BALB/C mice were purchased from B&K Universal, Stockholm, Sweden. Male and female mice were 6 to 14 weeks old with a weight ranging from 16 to 30 g. Each separate experiment was performed using animals within the same age and weight group. Animal housing conditions and experimental design were approved by the local animal ethical committee. Animals were fed and watered ad libitum.
Preparation of liposomal busulphan
Liposomal busulphan was prepared as described previously. 19 Briefly, lipids (L-␣-phosphatidylcholine, 1,2-dioleolyl-sn-glycero-3-phosphate and cholesterol) were dissolved in chloroform. Busulphan was added. The mixture of lipids and busulphan was dried by evaporation to a thin film coating the inside of a round glass vessel. Any traces of solvent were removed under a gentle stream of nitrogen. The mixture was then hydrated with 25 ml of glucose (50 mg/ml, pH 4.0). Multilamellar vesicles were formed by vortexing the lipid-aqueous mixture. The suspension was transferred to an extruder (LiposoFast 50; Avestin, Ottawa, Canada) and extruded five times under nitrogen pressure through two stacked polycarbonate filters with a pore size of 100 nm. Busulphan concentrations were measured before and after filtration to determine the entrapment efficiency. The mean concentration of busulphan was 0.22 Ϯ 0.05 mg/ml. The concentration of lipids was constant (15.9 mg/ml) in all experiments. Busulphan was encapsulated into liposomes under aseptic conditions. Vesicle size in the final liposomal preparation was 220 Ϯ 14 nm as described previously. 19 All solutions were prepared freshly before each experiment and stored in a refrigerator.
Other oral and intravenous forms
Busulphan for oral administration was either suspended in water (Bus/susp) or diluted in acetone as a stock solution which was mixed with water before administration (Bus/Ac). Busulphan for intravenous administration was dissolved in DMSO:ethanol:propyleneglycol mixed in ratio 0.35:0.25:0.40 (Bus/DMSO). The control group for CFU-GM experiments consists of untreated animals and animals treated with blank preparations containing solvent without busulphan: liposomal solution (LC) and organic solvent solution (DMSO).
Treatment
Liposomal busulphan and intravenous forms of busulphan were administered through tail vein while the oral forms were administered through a gastric tube. Two treatment schedules were used: single high dose and conditioning regimen-like schedule with busulphan administration twice a day for 4 days. All doses are presented as mg/kg Ϯ s. 
Bone marrow harvest and CFU-GM assay
Bone marrow was harvested 6 days after the single dose or on day 1, 3, 6 or 9 after the last dose of the conditioning regimen. Each treatment or control group consisted of a minimum of three animals at each time-point.
Mice were sacrificed under general anesthesia with ether. Both femurs were removed and bone marrow was flushed out under sterile conditions. CFU-GM assay was performed in MethoCult M3530. Briefly, the red cells were lysed with ammonium chloride solution for 10 min on ice. Cells were washed twice in PBS and cell number and viability were determined by trypan blue exclusion. Nucleated cells (1 × 10 5 ) were plated in 1.1 ml of MethoCult M3530 in 35 mm Petri dishes in triplicates. The plates were placed in 37°C, 5% CO 2 and 80% humidity incubator. Colonies Ͼ50 cells were counted on day 7 using an inverted microscope.
Blood sampling and busulphan determination
Blood samples for the bioavailability study were collected at time intervals 5, 10, 15 and 30 min and at 1, 2, 3, 4, 6, 8 and 10 h after the administration. The blood was sampled under general anesthesia with ether by heart puncture into tubes containing heparin. The blood was immediately centrifuged at 2000 g and plasma was frozen at −20°C until assay. Each time-point for all busulphan forms consisted of three animals.
Busulphan or liposomal busulphan and the internal standard (1,5-bis-methanesulfonoxy) pentane were converted to 1,4 diiodobutane and 1,5 diiodopentane, respectively. Busulphan concentrations were determined using gas chromatography with electron capture detection. 25 
Pharmacokinetics and statistics
The concentration-time curves were adjusted to the data sets via non-linear iterative least square regression analysis. Curve modelling was performed according to the classical one compartment open model. The pharmacokinetic parameters were calculated with PC using PCNONLIN version 1.1. Differences between two or more groups were assessed using the Mann-Whitney (U test) and Kruskal-Wallis analysis, whenever appropriate (Instat, Prism).
Results
Conditioning regimen with LB and busulphan administered orally
As can be seen in Figure 1 , all formulations of busulphan resulted in a significant decrease in CFU-GM compared with untreated animals.
The effect of LB was similar to that obtained after the administration of Bus/Ac. A significant decrease after both treatments was reached at day 1 (40-50% compared with untreated animals) and continued to day 9. However, a significant difference was observed at the sixth day of treatment, where the effect of Bus/Ac was higher (expressed as the number of CFU-GM per femur) on the bone marrow compared with that obtained after LB (30% and 42%, respectively). Both LB and Bus/Ac had a greater effect on the bone marrow than busulphan in suspension. The CFU-GM per femur obtained after treatment with busulphan in suspension was about 65% of that obtained in the untreated group. Mann-Whitney test showed significant P values (P Ͻ 0.05) when untreated animals were compared with all busulphan treated groups except busulphan suspension on day 3 and day 9. The administration of liposomes to the mice did not influence the colony-forming capacity of the bone marrow and no significant difference was found compared with the CFU-GM obtained from the control group (P Ͼ 0.05). Kruskal-Wallis test showed high significant difference (P = 0.0002) when all treatment groups were compared from day 1 to day 9. LB and Bus/Ac had a significantly higher effect on the bone marrow compared to that obtained after Bus/susp, while no difference was observed comparing LB with Bus/Ac. Also liposomal control showed a high significant difference comparing with LB and Bus/Ac (P = 0.003).
CFU-GM after the administration of single high dose
The effect of different administration forms of busulphan as a single dose on bone marrow harvested on day 6 is illustrated in Figure 2 . Busulphan (LB, Bus/Ac or Bus/DMSO) given to the mice as one single high dose reduced significantly (P Ͻ 0.01) the number of CFU-GM per femur to about 15-30% compared with untreated animals. Moreover, the administration of liposomes without busulphan did not affect the number of CFU-GM. However, a significant decrease (66%) was observed in CFU-GM number obtained after the administration of DMSO (P = 0.03).
Pharmacokinetics
The pharmacokinetic parameters for LB, Bus/DMSO, Bus/PO and Bus/Ac are listed in Table 1 Results are expressed as a mean Ϯ standard deviation. AUC standard = area under the curve concentration vs time standardized for the dose of 16 mg/kg; t . = half-life; Vdss = distribution volume; Cl = clearance; Bus/DMSO = busulphan dissolved in DMSO:propylenglycol:ethanol; LB = liposomal busulphan; Bus/Ac = busulphan dissolved in acetone and then in water; Bus/susp = busulphan suspended in water.
ics were fitted to the one compartment open model with first order absorption. Despite the identical doses administered orally to the mice, a higher peak-plasma concentration was observed (15.6 Ϯ 3.4 g/ml) after the administration Bus/Ac compared with that obtained after the administration of Bus/susp (10.2 Ϯ 0.9 g/ml). Peak plasma levels observed after the administration of Bus/DMSO was 26.6 Ϯ 3.4 g/ml, while after the administration of LB the peak plasma level was 13.0 Ϯ 2.7 g/ml.
The distribution volume after LB was significantly higher compared with that for Bus/DMSO (mean Ϯ s.d., 0.021 Ϯ 0.006 and 0.012 Ϯ 0.001 l/kg, respectively). The elimination half-lives after the administration of intravenous forms of busulphan were 1.3 and 1.6 h (LB and Bus/DMSO, respectively). For the oral forms, the half-lives were 1.4 and 2.4 h for Bus/susp and Bus/Ac, respectively. No significant differences were observed in the clearance or half-lives for busulphan administered in different forms.
Discussion
Busulphan as a high-dose therapy is included in many BMT protocols. However, busulphan treatment is associated with difficulties expressed in high inter-individual variation and toxicity related to high plasma levels. 9, 10, 26 In the pathophysiology of VOD, toxicity may be related to the exposure of small hepatic venules to high concentrations of busulphan after first-pass extraction of busulphan by the hepatic parenchyma. In this case, intravenous busulphan may greatly reduce the peak hepatic venous concentrations occurring after oral doses and may decrease the incidence of VOD.
Despite all attempts made to individualize and adjust busulphan doses, the ideal approach is an intravenous form of the drug. Recently we developed a novel form of busulphan encapsulated in liposomes. The results obtained from the study in the rat showed that the pharmacokinetic parameters of liposomal busulphan differed from that obtained after the administration of an intravenous form dissolved in DMSO. Higher distribution volume and longer elimination half-life were observed. Moreover a higher distribution of LB to the bone marrow was achieved. 19 Liposomes are good carriers for many drugs such as amphotericin B, methotrexate, cytosine arabinoside, platinum compounds and doxorubicin. [22] [23] [24] Liposomes are stable microscopic vesicles formed by phospholipids and similar amphipathic lipids. According to many studies there are four major factors affecting the in vivo behavior and the biodistribution of liposomes. 27 These factors are the presence of cholesterol, the amount of lipids, the size and the charge of liposomes. Small uncharged liposomes containing cholesterol were shown to be stable, to circulate longer time in the blood and to have higher distribution to the bone marrow.
In the present study, we investigated the effect of busulphan encapsulated in liposomes on bone marrow. Uncharged small liposomes (200 nm) containing cholesterol were used. Earlier studies of busulphan showed that myelosuppression after busulphan is time-and dose-dependent. [28] [29] [30] The most pronounced effect was reached 5 to 9 days after the treatment. 31 However, early effects were also reported. 32 Due to the high metabolic rate of mice, the single dose inducing profound myelosuppression is 50 mg/kg administered orally or intraperitoneally. 31, 33 However, it was shown that 70 mg/kg of busulphan divided in four doses administered in 2 weeks induced only chronic latent aplasia. 34 In the present investigation we followed the myelosuppressive effect for 9 days. The doses used were about 20 mg/kg to induce clear myelosuppression with minimal mortality.
The effect of liposomal busulphan on bone marrow was compared to that obtained after busulphan administered orally either in the form of a suspension or dissolved in acetone. The myelosuppression was assessed by CFU-GM assay and expressed as number of CFU-GM per femur. In the conditioning regimen, liposomal busulphan showed a myelosuppressive effect comparable with that obtained after the administration of Bus/Ac. The myelosuppression observed after the administration of both forms was significantly higher than that obtained after Bus/susp. This most likely is due to variability in bioavailability after the administration of Bus/susp (Table 1) . Acetone in small amounts does not have a toxic effect on the mice or the bone marrow as described previously. 35, 36 The administration of liposomes (without busulphan) did not show any effect on CFU-GM during the time intervals studied (Figure 1) .
Six days after administration the effect of a single high dose on the bone marrow was similar to that obtained after the conditioning regimen. These results may explain the fact that despite the great variability in conditioning protocols (4 mg/kg divided in four doses daily for 4 days vs 4 mg/kg once daily for 4 days 1,5,37 ) a similar effect on the marrow cells can be observed. There is no information available about whether high peak plasma concentration is more important for the eradication of the stem cells and leukemic cells than a steady state concentration for 4 days. The significant decrease in CFU-GM in the group treated with DMSO mixture may be due to secondary suppression of the bone marrow by DMSO toxicity since it is known that DMSO shows no direct toxicity to hematopoietic stem cells. 38 In our study we also treated animals with recently reported formulations for intravenous administration, busulphan dissolved in DMSO. Since we observed general and local toxicity and 5/13 animals died before the end of conditioning regimen we excluded this method of treatment. In the single dose treatment group only 1/44 animals died due to toxicity.
We investigated the pharmacokinetics of liposomal, oral and intravenous (dissolved in DMSO) busulphan in mice. The results (Table 1) showed that the bioavailability of the novel form (LB) was comparable with what we recently reported in a rat model. 19 The bioavailability was lower for both oral forms of busulphan than for LB. However, for oral busulphan in acetone the bioavailability was higher than that of Bus/susp. This probably is due to the presence of acetone which enhances the absorption of busulphan. Peak plasma levels observed after the administration of Bus/DMSO were higher compared to that obtained after the administration of LB which is due to the differences in the administered doses. The distribution volume was higher after the administration of LB compared to that for Bus/DMSO, which was also observed in the rat. 19 No significant differences were observed for the half-lives between different administration forms of busulphan, which is most likely due to the higher metabolic activity of the mice.
In summary, liposomal busulphan produced significant and durable myelosuppression without major side-effects. Myelosuppression was greater than that of orally administered busulphan. Pharmacokinetic parameters of liposomal busulphan are comparable with those of Bus/DMSO administered intravenously. The bioavailability for the novel form is also high and shows good reproducibility. Liposomal busulphan administered intravenously may overcome the problems with high inter-individual variability in bioavailability, difficulties with dose adjustment in infants, young children and patients with gastrointestinal complications. At the same time, an appropriate size of liposomes may target bone marrow and spleen and diminish drug exposure of the lung and CNS.
